Grace Capital’s Larimar Therapeutics LRMR Stock Holding History

Grace Capital’s Portfolio LRMR Stock Details LRMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-760	Closed	-$93K	–	220
2018 Q2	$93K	Buy	+760	New	+$64.6K	0.04%	189

Other funds holding LRMR

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Grace Capital's LRMR Position: Q3 2018 in Review

Grace Capital sold out of Larimar Therapeutics (LRMR) in Q3 2018, closing a stake of 760 shares — an estimated $93K sold.

Grace Capital first reported a position in LRMR in Q2 2018 and held it in 1 quarter. The position peaked at $93K in Q2 2018. 89 funds tracked by Wall St. Rank hold LRMR as of Q3 2018.

Grace Capital reported no remaining Larimar Therapeutics position as of Q3 2018 after selling out during the quarter.
Grace Capital sold 760 Larimar Therapeutics shares in Q3 2018, an estimated $93K.
Grace Capital first reported a position in Larimar Therapeutics in Q2 2018 and held it in 1 quarter.
Grace Capital's Larimar Therapeutics position peaked at $93K in Q2 2018.
89 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2018.

Based on Grace Capital's 13F filing for Q3 2018, filed 14 Nov 2018.